https://orcid.org/0000-0002-1652-7734
Figures & data
Figure 1. Flowchart illustrating inclusions, exclusions, and the final study population.
Figure 2. Approaches used to classify aggressive prostate cancer (PC).
Table 1. Characteristics of the study population of men with a primary invasive prostate cancer (PC) within the Janus Serum Bank cohort, diagnosed 2004 − 2009, stratified by year of diagnosis.
Figure 3. Sensitivity (A) and positive predictive values (B) with corresponding 95% confidence intervals for defining aggressive prostate cancer (PC) using Approaches 1 and 2 for cases diagnosed 2004–2009. The horisontal dashed lines and shaded bands represent point estimates with 95% confidence intervals for PCs diagnosed in 2007 in the SEER-18 cohort as reported by the PC3 Working Group [Citation16].
![Figure 3. Sensitivity (A) and positive predictive values (B) with corresponding 95% confidence intervals for defining aggressive prostate cancer (PC) using Approaches 1 and 2 for cases diagnosed 2004–2009. The horisontal dashed lines and shaded bands represent point estimates with 95% confidence intervals for PCs diagnosed in 2007 in the SEER-18 cohort as reported by the PC3 Working Group [Citation16].](/cms/asset/4adfcc43-e69d-4137-a891-c1c826505add/ionc_a_2175331_f0003_c.jpg)
Table 2. Number (n) of cases, and sensitivity and positive predictive values (PPVs), with 95% confidence intervals (CIs), for Approaches 1 and 2 to classify aggressive prostate cancer among cases in the Janus Serum Bank cohort diagnosed 2004–2009 and in 2007.
Supplemental Material
Download MS Word (16.8 KB)Supplemental Material
Download PDF (67.3 KB)Supplemental Material
Download PDF (55 KB)Supplemental Material
Download PDF (61.8 KB)Data availability statement
The data underlying this article cannot be shared publicly due to patient privacy. The data can be shared for research purposes on request to the Cancer Registry of Norway’s data delivery unit via Helsedata.no (https://helsedata.no/).